Insulin aspart: A review of its use in the management of type 1 and 2 diabetes mellitus

Drugs

Volumn 62, Issue 13, 2002, Pages 1945-1981

  Chapman, Therese M ^a   Noble, Stuart ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Diabetes mellitus; Insulin analogue; Insulin aspart; Pharmacodynamics; Pharmacokinetics; Therapeutic use

Indexed keywords

BIPHASIC INSULIN; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN LISPRO; ISOPHANE INSULIN;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; CHILD; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG RECEPTOR BINDING; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARYNGITIS; RECEPTOR AFFINITY; RESPIRATORY TRACT DISEASE; REVIEW; SYMPTOM; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 0036386080     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262130-00014     Document Type: Review

References (100)

1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2002 Jan; 25 (Suppl. 1): S5-S20
2. World Health Organisation. Definition, diagnosis and classification of diabetes mellitus and its complications [web page]. Available from: URL: http://www.diabetes.com.au/downloads/who_repon.pdf. Accessed 2002 Aug 13
3. World Health Organisation. Diabetes Mellitus Fact Sheet 138 [web page]. Available from: URL: http://www.who.int/inffs/en/fact138.html. Accessed 2002 Aug 13
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 Sep 30; 329 (14): 977-86
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 Sep 12; 352: 837-53
6. American Diabetes Association. Insulin administration. Diabetes Care 2002 Jan; 25 (Suppl. 1): S112-S115
7. Bolli GB. Rationale for using combinations of short-acting insulin analogue and NPH insulin at mealtime in the treatment of type 1 diabetes mellitus. J Pediatr Endocrinol Metab 1999; 12 (Suppl. 3): 737-44
8. Wilde MI, McTavish D. Insulin lispro: A review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 1997 Oct; 54 (4): 597-614
9. Novo Nordisk. Prescribing Information: NovoLog. Insulin aspart (rDNA origin) Injection [web page]. Available from: URL: http://www.novolog.com/physician/content/pe_pdfs/PhysicianInsert.pdf. Accessed 2002 Aug 13
10. Whittingham JL, Edwards DJ, Antson AA, et al. Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties for B28 Pro→Asp insulin analogues. Biochemistry 1998; 37: 11516-23
11. Gammeltoft S, Hansen BF, Dideriksen L, et al. Insulin aspart: A novel rapid-acting human insulin analogue. Expert Opin Invest Drugs 1999; 8 (9): 1431-41
12. Kurtzhals P, Schäffer L, Sørensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000 Jun; 49 (6): 999-1005
13. Drejer K, Kruse V, Larsen UD, et al. Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 1991 Nov; 40: 1488-95
14. Vølund A, Brange J, Drejer K, et al. In vitro and in vivo potency of insulin analogues designed for clinical use. Diabet. Med. 1991 Nov; 8 (9): 839-47
15. Kurtzhals P, Schäffer L, Drejer K, et al. Insulin receptor tyrosine kinase activation by insulin aspart and insulin analogues with a wide range of receptor binding affinities [abstract no. 667]. Diabetologia 1999 Aug; 42 (Suppl. 1): A179
16. Trüb T, Hey A, Sorensen AR, et al. Growth promoting activity of insulin aspart and other insulin analogues [abstract no. 666]. Diabetologia 1999 Aug; 42 (Suppl. 1): 179
17. Kang S, Creagh FM, Ara J, et al. Insulin analogues and human insulin: Near-equivalent in vivo biological activity in healthy males in spite of widely different in vitro potencies [abstract no. 969]. Diabetes 1991 May; 40 (Suppl. 1): 243A
18. Frier BM, Ewing FME, Lindholm A, et al. Symptomatic and counterregulatory hormonal responses to acute hypoglycaemia induced by insulin aspart and soluble human insulin in Type 1 diabetes. Diabetes Metab Res Rev 2000 Jul; 16 (4): 262-8
19. Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet 2001; 40 (9): 641-59
20. Heller SR, Robinson RTCE, Harris ND, et al. Soluble insulin and the rapid-acting analogue insulin aspart have similar effects upon ventricular repolarization [abstract no. 891]. Diabetologia 1999 Aug; 42 (Suppl. 1): 237
21. Heinemann L, Heise T, Jorgensen LN, et al. Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabet. Med. 1993; 10: 535-9
22. Heinemann L, Kapitza C, Starke AA, et al. Time-action profile of the insulin analogue B28Asp. Diabet Med 1996 Jul; 13 (7): 683-4
23. Heinemann L, Weyer C, Rave K, et al. Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp. Exp. Clin. Endocrinol. Diabetes. 1997; 105: 140-4
24. Heinemann L, Weyer C, Rauhaus M, et al. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998 Nov; 21 (11): 1910-4
25. Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999 Sep; 22 (9): 1501-6
26. Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999 May; 55 (3): 199-203
27. Kaku K, Matsuda M, Urae A, et al. Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. Diabetes Res Clin Pract 2000 Aug; 49: 119-26
28. B28) in healthy subjects. Diabetes Care 1991 Nov; 14 (11): 1057-65
29. B28) on meal-related plasma glucose excursions in type I diabetic subjects. Diabetes Care 1991 Jul; 14 (7): 571-7
30. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart: a randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 1999 May; 22 (5): 801-5
31. Lutterman JA, Pijpers E, Netten PM, et al. Glycaemic control in IDDM patients during one day with injection of human insulin or the insulin analogues insulin X14 and insulin X14 (+Zn). Berger M, Gries F. Frontiers in insulin pharmacology: international symposium, Hamburg. Stuttgart: Thieme Medical Publishers, 1993: 102-9
32. Rosenfalck AM, Thorsby P, Kjems L, et al. Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 2000 Mar; 37 (1): 41-6
33. Perriello G, Avogaro A, Emanuele B, et al. Superior meal-time glucose control with insulin aspart (NovoLog®) compared with human insulin in both normal-weight and overweight people with type 2 diabetes - a randomized, stratified, double-blind, crossover trial [abstract no. 452-P]. Diabetes 2002 Jun; 51 (Suppl. 2): A111
34. Plank J, Wutte A, Goerzer E, et al. A direct comparison of insulin analogs aspart and lispro in type 1 diabetic patients [abstract no. 213-OR]. Diabetes 2002 Jun; 51 (Suppl. 2): A52
35. Hamilton-Wessler M, Buchanan T, Hathout E, et al. Time-action profile for intravenously infused insulin aspart and insulin lispro in type 1 diabetic subjects [abstract no. 403-P]. Diabetes 2002 Jun; 51 (Suppl. 2): A99
36. Mortensen HB, Lindholm A, Olsen BS, et al. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr 2000 Jul; 159 (7): 483-8
37. Brunner GA, Hirschberger S, Sendlhofer G, et al. Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus. Diabet Med 2000 May; 17 (5): 371-5
38. Jovanovic L, Aquistapace M, Pettitt DJ. Postprandial glycemic control is provided by either preprandial or postprandial administration of insulin aspart in type 1 diabetes [abstract no. 415-P]. Diabetes 2002 Jun; 51 (Suppl. 2): A102
39. Jacobsen LV, Søgaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000 Aug; 56 (5): 399-403
40. Weyer C, Heise T, Heinemann L, et al. Insulin aspart in a 30/70 premixed formulation - pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997 Oct; 20 (10): 1612-4
41. Hermansen K, Colombo M, Storgaard H, et al. Improved post-prandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002 May; 25 (5): 883-8
42. Hermansen K, Vaaler S, Madsbad S, et al. Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes. Metabolism 2002 Jul; 51 (7): 896-900
43. Kapitza C, Nosek L, Lindholm A, et al. Postprandial dosing of the "lowmix" biphasic insulin aspart [abstract no. 809]. Diabetologia 2001; 44 (Suppl. 1): A212
44. Pettitt DJ, Ospina P, Jovanovic L, et al. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus (GDM) [abstract no. 1784-P]. Diabetes 2002 Jun; 51 (Suppl. 2): A434-5
45. McSorley PT, Bell PM, Jacobsen LV, et al. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002; 24 (4): 530-9
46. Gallagher A, Home PD. The effect of insulin aspart in post-prandial lipid profile in type 2 diabetes [abstract no. 1932-PO]. Diabetes 2002 Jun; 51 (Suppl. 2): A470
47. Lyness W, Tyler JF, Lawrence A. Renal impairment does not affect insulin aspart pharmacokinetics in type 1 diabetes [abstract no. 842-PO]. Diabetes 2001 Jun; 50 (Suppl. 2): A441-2
48. Lyness W, Tyler J, Lawrence A. Pharmacokinetics of the rapid-acting insulin-analog, insulin aspart, is independent of hepatic function [abstract no. 1843-PO]. Diabetes 2001 Jun; 50 (Suppl. 2): A442
49. Lyness W, Tyler J, Lawrence A. BMI does not affect insulin aspart pharmacokinetics in type I diabetes [abstract no. 499-P]. Diabetes 2001 Jun; 50 (Suppl. 2): A124
50. Hedman CA, Lindstrom T, Arnqvist HJ. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes [letter]. Diabetes Care 2001 Jun; 24 (6): 1120-1
51. Lindholm A, Sasaki T, Edwards A, et al. Dose dependency in absorption in insulin aspart in healthy Caucasians and Japanese [abstract no. 1840-PO]. Diabetes 2001 Jun; 50 (Suppl. 2): A441
52. Jensen I, Kruse V, Larsen UD. Scintigraphic studies in rats: Kinetics of insulin analogues covering wide range of receptor affinities. Diabetes 1991 May; 40 (5): 628-32
53. Plum A, Larsen PS, Larsen UD, et al. Determination of in vitro plasma protein binding of insulin aspart and insulin detemir by equilibrium dialysis [abstract no. 886]. Diabetologica 1999; 42 (Suppl 1): A236
54. Home PD, Lindholm A, Hylleberg B, et al. Improved glycemic control with insulin aspart - a multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care 1998 Nov; 21 (11): 1904-9
55. Home PD, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000 Nov; 17 (11): 762-70
56. Raskin P, Guthrie RA, Leiter L, et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000 May; 23 (5): 583-8
57. Tamás G, Marre M, Astorga R, et al. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Res Clin Pract 2001 Nov; 54: 105-14
58. Tsalikian E. Insulin aspart in pediatric and adolescent patients with type 1 diabetes [abstract no. 767]. Diabetologia 2000 Aug; 43 (Suppl. 1): 200
59. DeVries JH, Lindholm A, Heine RJ, et al. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in type 1 diabetes [abstract no. 801]. Diabetologia 2001; 44 (Suppl. 1): 209
60. Bretzel RG, Medding J, Hirschberger S, et al. Insulin aspart efficacy and safety compared to human soluble insulin and human premix insulin (30/70) in patients with type 2 diabetes mellitus [abstract no. 804]. Diabetologia 2001; 44 (Suppl. 1): 209
61. McGill J, Raskin P, Kilo C, et al. Human insulin analog, insulin aspart, is a mealtime insulin comparable to human insulin in type 2 diabetes [abstract no. 894]. Diabetologia 1999 Aug; 42 (Suppl. 1): A238
62. Amiel S, Home PD, Jacobsen JL, et al. Insulin aspart safe for long-term treatment [abstract no. 802]. Diabetologia 2001; 44 (Suppl. 1): A209
63. Bode B, Weinstein R, Bell D, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care 2002 Mar; 25 (3): 439-44
64. Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19: 393-9
65. Boehm B, Home P, Kamp N, et al. Biphasic insulin aspart and biphasic human insulin compared in type 2 diabetic subjects [abstract no. 808]. Diabetologia 2001; 44 (Suppl. 1): 210
66. Danne T, Aaman J, Schober E, et al. Preprandial vs. postprandial insulin aspart treatment in type I diabetic children and adolescents [abstract no. 986]. Diabetologia 2001; 44 (Suppl. 1): 257
67. Hoogwerf B, Raskin P, Jovanovic L, et al. Insulin aspart - a mealtime alternative to soluble human insulin in type 1 diabetes [abstract no. 892]. Diabetologia 1999 Aug; 42 (Suppl. 1): 237
68. Bode B, Weinstein R, Bell D, et al. Insulin aspart efficacy and safety compared to buffered regular insulin (Velosulin®) and insulin lispro for continuous subcutaneous insulin infusion [abstract no. 474-P]. Diabetes 2001 Jun; 50 (Suppl. 2): A106
69. Bretzel RG, Hirschberger S, Medding J, et al. A multi-centre efficacy and safety comparison of insulin aspart, human soluble insulin and human premix insulin (70/30) in patients with type 2 diabetes mellitus [abstract no. 379-P]. Diabetes 2002 Jun; 51 (Suppl. 2): A93
70. Raskin P, Bode B, Marks JB, et al. Insulin aspart (IAsp) is as effective in continuous subcutaneous insulin infusion as in multiple daily injections for patients with type 2 diabetes [abstract no. 515-P]. Diabetes 2002 Jun; 51 (Suppl. 2): A128
71. Warren ML, Conway MJ, Klaff LJ, et al. Clinical experience with postprandial dosing of NovoLog Mix 70/30 in elderly subjects with type 2 diabetes [abstract no. 1999-PO]. Diabetes 2002 Jun; 51 (Suppl. 2): A486
72. Kilo C, Mezitis NH, Nadeau DA, et al. Dinnertime Novolog mix 70/30 in combination with metformin - a combination to use? [abstract no. 527-P] Diabetes 2002 Jun; 51 (Suppl. 2): A130
73. Kvapil M, Mikolajczyk-Swatko A, Ostergaard AH, et al. Biphasic insulin aspart 30 combined with metformin provides better glycemic control in poorly controlled type 2 diabetic patients [abstract no. 424-P]. Diabetes 2002 Jun; 51 (Suppl. 2): A104
74. Bott U, Ebrahim S, Hirschberger S, et al. Effect of the insulin analogue insulin aspart on quality-of-life and treatment satisfaction in type 1 diabetic patients [abstract no. 893]. Diabetologia 1999 Aug; 42 (Suppl. 1): 237
75. Home PD, Boehm BO, Bott U, et al. Treatment with premixed insulin aspart 30 in type 1 and type 2 diabetes: a randomized 12-week comparison [abstract no. P220]. Diabetes Res Clin Pract 2000 Sep; 50 (Suppl. 1): S37
76. Colagiuri S, Heller S, Vaaler S, et al. Insulin aspart reduces the frequency of nocturnal hypoglycaemia in patients with type 1 diabetes [abstract no. 805]. Diabetologia 2001; 44 (Suppl. 1): 210
77. Lindholm A, Jensen LB, Home PD, et al. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002 May; 25 (5): 876-82
78. Lindholm A, Andersen HF, Gall M. Safety profile of insulin aspart [abstract no. P110]. Diabet Med 2000 Mar; 17 (Suppl. 1): 62
79. NovoNordisk. NovoLog® Clinical Overview. (Data on file). 2001 Jul
80. Novo Nordisk. NovoRapid®: Summary of product characteristics [web page]. Available from: URL: http://www.novonordisk.co.uk/view.asp?ID=70. [Accessed 2002 Aug 13]
81. Novo Nordisk UK. (Data on file). 2002
82. Bolli GB, Di Marchi RD, Park GD, et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999 Oct; 42 (10): 1151-67
83. Halberg IB, Jacobsen LV, Dahl UL. A study on self-mixing insulin aspart with NPH insulin in the syringe before injection [abstract no. 0448]. Diabetes 1999 May; 48 (Suppl. 1): A104
84. NovoNordisk. Information for the patient. NovoLog® (Insulin aspart [rDNA origin] Injection) [web page]. Available from: URL: http://www.novolog.com/consumer/content/PF/PatientInsert.pdf. [Accessed 2002 Aug 13]
85. Aventis Pharmaceuticals Inc. Prescribing information: insulin glargine injection [web page]. Available from: URL: http://www.aventispharma-us.com/pis/lantus_txt.html. [Accessed 2002 Aug 13]
86. Novo Nordisk. Prescribing information: NovoLog Mix 70/30®. 2002 Jul
87. Novo Nordisk. NovoMix30® Penfill® and FlexPen®: Summary of product characteristics [web page]. Available from: URL: http://www.novonordisk.co.uk/view.asp?ID=1496. [Accessed 2002 Aug 13]
88. Novo Nordisk. NovoRapid® and NovoMix30®: Treatment Guidelines for Adults [web page]. Available from: URL: http://www.novomix30.com/novomix/treatment01.asp. [Accessed 2002 Aug 13]
89. Setter SM, Corbett CF, Campbell RK, et al. Insulin aspart: a new rapid-acting insulin analog. Ann Pharmacother 2000 Dec; 34 (12): 1423-31
90. Chehade JM, Mooradian AD. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs 2000 Jul; 60 (1): 95-113
91. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE system of intensive diabetes self-management - 2002 update. Endocrine Practice 2002 Jan/Feb 28; 8 (Suppl. 1): 41-86
92. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-30
93. European IDDM Policy Group 1993. Consensus guidelines for the management of insulin-dependent (type 1) diabetes. Diabet Med 1993; 10: 990-1005
94. Brange J, Owens DR, Kang S, et al. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990 Sep; 13 (9): 923-54
95. McKeage K, Goa KL. Insulin Glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Drugs 2001; 61 (11): 1599-624
96. Buse JB. Insulin analogues. Curr Opin Endocrinol Diabetes 2001; 8 (2): 95-100
97. Holleman F, Hoekstra JBL. Drug therapy: insulin lispro. N Engl J Med 1997 Jul; 337 (3): 176-83
98. Vajo Z, Fawcett J, Duckworth WC. Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev 2001 Oct; 22 (5): 706-17
99. Mohn A, Dungar DB, Chiarelli F, et al. The potential role of insulin analogues in the treatment of children and adolescents with type 1 diabetes mellitus. Diab. Nutr. Metab. 2001; 14 (6): 349-57
100. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial Research Group. Protocol abstract [web page]. Available from: URL: http://www.accordtrial.org/public/purpose.cfm. [Accessed 2002 Aug 13]